217 related articles for article (PubMed ID: 33410766)
21. Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1α and promotes cancer cell proliferation.
Jeon YK; Park SG; Choi IW; Lee SW; Lee SM; Choi I
Biochem Biophys Res Commun; 2015 Apr; 459(2):277-283. PubMed ID: 25725157
[TBL] [Abstract][Full Text] [Related]
22. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
Front Immunol; 2022; 13():984172. PubMed ID: 36159808
[TBL] [Abstract][Full Text] [Related]
23. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
25. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.
Ohaegbulam KC; Liu W; Jeon H; Almo SC; Zang X
Oncotarget; 2017 Oct; 8(47):82740-82753. PubMed ID: 29137299
[TBL] [Abstract][Full Text] [Related]
26. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
27. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
[TBL] [Abstract][Full Text] [Related]
28. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
[TBL] [Abstract][Full Text] [Related]
29. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
30. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.
John P; Pulanco MC; Galbo PM; Wei Y; Ohaegbulam KC; Zheng D; Zang X
Nat Commun; 2022 May; 13(1):2506. PubMed ID: 35523809
[TBL] [Abstract][Full Text] [Related]
31. Decursin promotes HIF-1α proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Ge Y; Yoon SH; Jang H; Jeong JH; Lee YM
Phytomedicine; 2020 Nov; 78():153318. PubMed ID: 32896707
[TBL] [Abstract][Full Text] [Related]
32. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
33. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.
Podojil JR; Glaser AP; Baker D; Courtois ET; Fantini D; Yu Y; Eaton V; Sivajothi S; Chiang M; Das A; McLaughlin KA; Robson P; Miller SD; Meeks JJ
Oncoimmunology; 2020; 9(1):1744897. PubMed ID: 32363111
[TBL] [Abstract][Full Text] [Related]
34. Generation and characterization of B7-H4/B7S1/B7x-deficient mice.
Suh WK; Wang S; Duncan GS; Miyazaki Y; Cates E; Walker T; Gajewska BU; Deenick E; Dawicki W; Okada H; Wakeham A; Itie A; Watts TH; Ohashi PS; Jordana M; Yoshida H; Mak TW
Mol Cell Biol; 2006 Sep; 26(17):6403-11. PubMed ID: 16914726
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneous Expression of PD-L1, B7x, B7-H3, and HHLA2 in Pulmonary Sarcomatoid Carcinoma and the Related Regulatory Signaling Pathways.
Wang F; Cali Daylan AE; Deng L; Yang J; Sharma J; Su C; Li S; Zang X; Halmos B; Borczuk A; Cheng H
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444481
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
Chand D; Dhawan D; Sankin A; Ren X; Lin J; Schoenberg M; Knapp DW; Zang X
Bladder Cancer; 2019 Jan; 5(1):63-71. PubMed ID: 30854414
[TBL] [Abstract][Full Text] [Related]
37. B7-H4, a promising target for immunotherapy.
Wang JY; Wang WP
Cell Immunol; 2020 Jan; 347():104008. PubMed ID: 31733822
[TBL] [Abstract][Full Text] [Related]
38. T cell coinhibition and immunotherapy in human breast cancer.
Janakiram M; Abadi YM; Sparano JA; Zang X
Discov Med; 2012 Oct; 14(77):229-36. PubMed ID: 23114578
[TBL] [Abstract][Full Text] [Related]
39. KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.
Li Y; Lv C; Yu Y; Wu B; Zhang Y; Lang Q; Liang Z; Zhong C; Shi Y; Han S; Xu F; Tian Y
J Adv Res; 2023 May; 47():137-150. PubMed ID: 35933091
[TBL] [Abstract][Full Text] [Related]
40. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
